Skip to main content
    S

    Sagimet Biosciences Inc. Series A Common Stock (SGMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.98
    -0.82 (-9.32%)

    Market Cap: $565.85M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(9/13)
    Avg Surprise
    -506.85%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.26
    Range$-0.34 - $-0.20
    11 analysts
    EPS RevisionsNo revisions (7d)
    2
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.26+0.1%
    60d ago$-0.26+0.1%
    30d ago$-0.26-2.0%
    7d ago$-0.26+1.0%
    Current$-0.26
    Revenue Consensus
    $0
    Range$0 - $0
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.25
    Range$-0.44 - $-0.09
    11 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.25---
    Sep 26EST
    		-$-0.26---
    Jun 26
    Reported Aug 11
    		$-0.26$-0.28+7.14%Beat+18.8%
    Mar 26
    Reported May 12
    		$-0.33$-0.35+5.71%Beat+41.1%
    Dec 25
    Reported Mar 11
    		$-0.29$-0.40+27.79%Beat+42.0%
    Sep 25
    Reported Nov 13
    		$-0.40$-0.39-2.56%Miss+11.1%
    Jun 25
    Reported Aug 13
    		$-0.32$-0.50+36.00%Beat-28.0%
    Mar 25
    Reported May 8
    		$-0.56$-0.71+21.13%Beat-143.5%
    Dec 24
    Reported Mar 12
    		$-0.50$-0.65+23.08%Beat+35.9%
    Sep 24
    Reported Nov 14
    		$-0.45$-0.40-12.50%Miss-28.6%
    Jun 24
    Reported Aug 14
    		$-0.25$-0.35+28.57%Beat+99.3%
    Mar 24
    Reported May 15
    		$-0.23$-0.38+39.47%Beat+47.7%
    Dec 23
    Reported Mar 25
    		$-0.78$-0.58-34.48%Miss-
    Sep 23
    Reported Nov 13
    		$-0.35N/A+56.25%Beat-
    Jun 23
    Reported Jul 14
    		$-35.80$-0.52-6784.62%Miss-
    Mar 23
    Reported May 31
    		$-0.44$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-6.23EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-24.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio45.02xQuick Ratio45.02x
    Trading Statistics
    Beta3.49Avg Volume1.48M
    52-Week High$11.4552-Week Low$4.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.97
    SMA 20$9.62
    SMA 50$9.96
    SMA 200$7.27
    EMA 10$8.93
    EMA 20$9.36
    EMA 50$9.43
    EMA 200$7.89

    MACD

    Line: -0.44Signal: -0.28Hist: -0.16

    ADX

    ADX: 20.0+DI: 18.8-DI: 28.8

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down100.0
    PSAR$10.02

    Bollinger Bands

    Upper Band$11.47
    Lower Band$7.76
    %B Position3862%(Upper)
    Band Width0.06

    RSI (14-Day)

    Neutral
    32.0

    Momentum Oscillators

    Stoch %K11.8
    Stoch %D15.2
    Williams %R-96.7
    ROC (10d)-14.5%
    Momentum-1.35
    CCI (20d)-123.2
    MFI (14d)39.5

    Volatility Measures

    ATR (14d)$0.64(8.0%)
    StdDev (20d)0.93
    Hist Vol80.7%(High)

    Volume Flow

    VWAP$8.20
    OBV90.8M
    AD Line-12.8M
    CMF (20d)-0.120

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio1.5x(High)
    VWMA (20d)$9.54

    Pivot Points

    R3$9.46
    R2$9.30
    R1$9.05
    Pivot Point$8.89
    S1$8.64
    S2$8.48
    S3$8.23

    Advanced Oscillators

    TSI-19.23
    Ultimate Osc46.8
    KST-139.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$2.00M
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$2.00M
    Operating Expenses$15.82M$11.71M$10.77M$14.33M$11.93M$19.86M$18.20M$16.90M$10.59M$8.77M$9.47M$9.45M
    R&D$11.54M$7.00M$6.73M$9.73M$7.25M$15.34M$14.22M$12.65M$6.31M$5.26M$5.66M$4.96M
    SG&A$4.28M$4.72M$4.03M$4.60M$4.68M$4.52M$3.98M$4.25M$4.28M$3.51M$3.81M$4.49M
    Operating Income$-15,818,000$-11,713,000$-10,765,000$-14,334,000$-11,925,000$-19,865,000$-18,195,000$-16,902,000$-10,589,000$-8,768,000$-9,466,000$-7,452,000
    Interest Income$1.86M$1.06M$1.20M$1.43M$1.54M$1.69M$1.99M$2.28M$2.47M$2.14M$1.31M$1.09M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-13,953,000$-10,650,000$-9,568,000$-12,908,000$-10,386,000$-18,176,000$-16,201,000$-14,619,000$-8,118,000$-6,629,000$-8,151,000$-6,353,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-13,953,000$-10,650,000$-9,568,000$-12,908,000$-10,386,000$-18,176,000$-16,201,000$-14,619,000$-8,118,000$-6,629,000$-8,151,000$-6,353,000
    EBITDA$-15,835,000$-11,853,000$-10,465,000$-14,262,000$-12,151,000$-20,400,000$-18,251,000$-17,429,000$-11,066,000$-8,961,000$-9,464,000$-7,448,000
    EBIT$-15,818,000$-11,713,000$-10,765,000$-14,334,000$-11,925,000$-19,865,000$-18,195,000$-16,902,000$-10,589,000$-8,768,000$-9,466,000$-7,448,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SGMT

    News

    Sagimet Biosciences Announces Major Equity Financing Agreement

    Sagimet Biosciences Inc. has secured approximately $107.5 million through an equity financing agreement, involving the sale of Series A common stock and pre-funded warrants. The capital infusion will fund a Phase 3...

    TipRanks•10/1/26•Bullish

    Sagimet Reports Strong Phase 3 Acne Trial Results

    Sagimet Biosciences reported strong 52-week Phase 3 results for its acne treatment, denifanstat, reinforcing prior success in Chinese trials and NMPA NDA acceptance. The company plans to initiate a U.S. Phase 3 trial...

    TipRanks•9/30/26•Bullish

    Sagimet Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since April 2025 -- Data Talk

    Sagimet Biosciences (SGMT) experienced a significant drop of over 15% in premarket trading on Thursday, putting the company on track for its largest single-day percentage decrease since April 2025. This downturn follows...

    Moomoo•9/25/26•Bearish

    Sagimet Highlights Q2 Results and Dermatology Focus Shift

    Sagimet Biosciences (SGMT) reported its Q2 2026 results, announcing a strategic pivot towards dermatology. The company plans to advance its lead FASN inhibitor, denifanstat...

    TipRanks•8/11/26•Somewhat-Bullish

    BlackRock (NYSE: BLK) reports 7.8% beneficial stake in Sagimet Biosciences (SGMT)

    BlackRock, Inc. has disclosed a 7.8% beneficial ownership stake in Sagimet Biosciences Inc. (SGMT) Class A Stock, as reported in a Schedule 13G filing. As of June 30, 2026...

    Stock Titan•7/30/26•Neutral

    SGMT Valuation and Fair Value

    P/E
    -6.2x
    P/B
    1.7x
    See GNG's fair value

    SGMT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -24.4%

    SGMT Competitors

    CompanyTicker
    DBV TechnologiesDBVT
    Silence Therapeutics PLCSLN
    Prime Medicine, Inc. Common StockPRME
    Valneva SE ADRVALN
    Orthopediatrics CorpKIDS
    ZimVie IncZIMV
    CorMedix IncCRMD
    Bright Minds Biosciences IncDRUG

    Sector: Healthcare

    SGMT Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    2
    Buy
    9
    Hold
    0
    Sell
    1
    Strong Sell
    0

    SGMT Bull Case vs Bear Case

    Bull case

    • SGMT beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 91.7% of SGMT's analyst ratings are Buy or Strong Buy.

    SGMT Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    13.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.26
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 4 down

    Frequently Asked Questions About SGMT

    Does SGMT pay dividends?

    Sagimet Biosciences Inc. Series A Common Stock (SGMT) does not currently pay a regular dividend.

    What is SGMT's market cap?

    Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a market capitalization of $565.85M with a current stock price of $7.98.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In